Read more

October 19, 2021
1 min read
Save

Promising results reported from Notal Home OCT feasibility study

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A home-based OCT imaging study in patients with wet age-related macular degeneration demonstrated ease of use and good image quality, according to a press release from Notal Vision.

“The results of the first U.S. study confirm the key target product profile requirements of our Home OCT program,” Kester Nahen, PhD, CEO of Notal Vision, said in the release.

In the feasibility study, 15 patients with an average age of 70.4 years used the Notal Home OCT device to produce self-imaged scans over 90 days, totaling 2,374 scans.

The study “showed the device’s ease of use, good image quality, compliant self-imaging and spatiotemporal tracking of retinal fluid in an elderly wet AMD patient population,” the release said.

Quality criteria were met in 93% of scans, enabling the artificial intelligence algorithm to perform fluid quantification, the release said.

The device is in the process of obtaining FDA clearance.